Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.390 | Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment | Prof. MOK Tony Shu Kam |
| 2013.089 | ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S) | Prof. MOK Tony Shu Kam |
| 2018.123 | Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2020.532 | A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2019.584 | A randomized, open-label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1≥ 50% |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2018.465 | Brigatinib in Patients With Anaplastic Lymphoma Kinase- Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2022.075 | An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2021.631 | A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2016.458 | eXALT3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2017.423 | A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC) (POSEIDON) |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2014.528 | Phase 1/2 Study of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations | Prof. MOK Tony Shu Kam |
| 2015.607 | An Open-label Randomized Multinational Phase 3 Trial of Nivolumab versus Docetaxel in Previously Treated Subjects with Advanced or Metastatic Non-small Cell Lung Cancer |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2014.256 | RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL-CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2015.582 | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2013.572 | A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2016.086 | Phase II Study of AZD9291 in patients with advanced stage non-small cell lung cancer following prior EGFR TKI Therapy with EGFR and T790M mutations detected in plasma circulating tumor DNA |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2013.525 | A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib | Prof. MOK Tony Shu Kam |
| 2015.443 | A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of ATEZOLIZUMAB (anti-PD-L1 antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer | Prof. MOK Tony Shu Kam |
| 2016.291 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2015.238 | A multi-center, open -label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2015.255 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+NAB-PACLITAXEL FOR CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON−SMALL CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2016.597 | Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2017.388 | A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2014.666 | TIGER-1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-line Treatment of Patients with EGFR-mutant Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) | Prof. MOK Tony Shu Kam |
| 2013.461 | A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment | Prof. MOK Tony Shu Kam |
| 2007.246 | A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer | Prof. MOK Tony SK |
| 2008.249 | Randomized, Open Label, Phase III Trial of CP-751, 871 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer | Prof MOK Tony, S.K. |
| 2008.023 | Mechanisms for Cognitive Impairment in Chinese Patients with Confluent White Matter Lesion: Analysis of 99 Structural Brain Regions Using a Hybrid Volumetric and Surface Warping | Prof Mok Vincent |
| 2013.660 | Evaluation of the need of CM services for stroke patients in Hong Kong | Prof. MOK Vincent |
| 2014.276 | Danshen and Gegen in improving Cerebral Haemodynamics in Cerebral White Matter Hyperintensities: A Pilot Study | Prof. MOK Vincent |
| 2014.213 | Physiological basis of motor facilitation by visual cues in Parkinson's disease | Prof Mok Vincent |
| 2020.536 | Enhancing Use of Telemedicine among Older People amid COVID-19 In Asia (EUTOPIA ) | Prof. MOK Vincent |
| 2019.371 | Biomarkers in Neurodegenerative Diseases (NDD Registry) |
Prof. MOK Vincent 莫仲棠 |
| 2023.348 | Brain Heath Service for Prevention of AD |
Prof. MOK Vincent 莫仲棠 |
| 2013.681 | A nested case-control study to investigate microRNA as a screening biomarker for asymptomatic elders with white matter hyperintensities at risk of incident dementia and stroke | Prof. Mok Vincent C T |
| 2012.167 | MicroRNA expression pattern in stroke patients: a pilot study | Prof Mok Vincent C.T |
| 2016.065 | Identifying Fluctuators in Parkinson's Disease with Objective Assessment Technology |
Prof. MOK Vincent C.T. 莫仲棠 |
| 2015.449 | mPower - Mobile Parkinson’s Disease Study |
Dr. MOK Vincent C.T. 莫仲棠 |
| 2015.574 | Establishment of reference genome of Hong Kong population for biomarker identification in Alzheimer's disease |
Prof. MOK Vincent C.T. 莫仲棠 |
| 2017.109 | Plasma microRNA dysregulation for the identification of smal vessel disease |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2014.227 | A multicenter, double-blind, placebo-controlled, randomised, paralle-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease | Prof. MOK Vincent Chung Tong |
| 2017.337 | Impact of oculomotor deficits on dynamic visual functions in Parkinson's Disease |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2017.621 | A novel imaging marker facilitates early identification of small vessel disease |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2017.254 | Identifying biomarkers in Alzheimer’s disease |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2016.404 | Hepcidin as Diagnostic Marker for PD and Other Neurodegenerative Diseases |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2017.576 | An alternative method to identify cerebral small vessel disease using retinal vascular imaging |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2015.682 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2016.176 | A prospective cohort study: The use of iPhone ECG monitoring in acute ischemic stroke during hospitalization in Hong Kong |
Prof. MOK Vincent Chung Tong 莫仲棠 |
| 2014.362 | A retrospective cross-sectional study of different types of Traditional Chinese Medicine for post-stroke rehabilitation in Hong Kong | Prof. MOK Vincent Chung Tong |
| 2016.318 | Cerebral white matter hyperintensities, connectivity disruption and cortical thinning in elderly with small vessel disease |
Prof. MOK Vincent Chung Tong 莫仲棠 |
Page 167 of 254.